Skip to main content

Advertisement

SpringerLink
Log in

Aromatase inhibitor therapy and hair loss among breast cancer survivors

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The objective of this study was to examine the associations between aromatase inhibitor therapy and hair loss or hair thinning among female breast cancer survivors. Data were analyzed from 851 female breast cancer survivors who responded to a hospital registry-based survey. Data on hair loss, hair thinning, demographic characteristics, and health habits were based on self-report; data on aromatase inhibitor therapy were collected on the survey and verified using medical record review. Logistic regression was used to estimate the odds ratios (ORs) and 95 % confidence intervals (CIs) for the associations between aromatase inhibitor therapy and the hair outcome variables adjusted for potential confounders, including age and chemotherapy treatment. The results showed that 22.4 % of the breast cancer survivors reported hair loss and 31.8 % reported hair thinning. In the confounder-adjusted analyses, breast cancer survivors who were within 2 years of starting aromatase inhibitor treatment at the time of survey completion were approximately two and a half times more likely to report reporting hair loss (OR 2.55; 95 % CI 1.19–5.45) or hair thinning (OR 2.33; 95 % CI 1.10–4.93) within the past 4 weeks compared to those who were never treated with an aromatase inhibitor. Current aromatase inhibitor use for two or more years at the time of the survey and prior use were significantly associated with hair thinning (current users, ≥2 years: OR 1.86; prior users: OR 1.62), but not hair loss. Findings from this study suggest that aromatase inhibitor use is associated with an increased risk of hair loss and hair thinning independent of chemotherapy and age; these side effects are likely due to the substantial decrease in estrogen concentrations resulting from treatment with this drug. Future research should focus on examining these associations in a prospective manner using more detailed and objective measures of hair loss and thinning.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brodie AM, Njar VC (1998) Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. J Steroid Biochem Mol Biol 66:1–10

    Article  PubMed  CAS  Google Scholar 

  2. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271

    Article  PubMed  CAS  Google Scholar 

  3. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62

    Article  PubMed  CAS  Google Scholar 

  4. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462

    Article  PubMed  CAS  Google Scholar 

  5. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757

    Article  PubMed  Google Scholar 

  6. Jones SE, Cantrell J, Vukelja S, Pippen J, O’Shaughnessy J, Blum JL et al (2007) Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol 25:4765–4771

    Article  PubMed  CAS  Google Scholar 

  7. Gallicchio L, MacDonald R, Wood B, Rushovich E, Helzlsouer KJ (2012) Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy. Climacteric 15:339–349

    Article  PubMed  CAS  Google Scholar 

  8. Cella D, Fallowfield LJ (2008) Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107:167–180

    Article  PubMed  CAS  Google Scholar 

  9. Kirk MC, Hudis CA (2008) Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 8:155–161

    Article  PubMed  Google Scholar 

  10. Fontaine C, Meulemans A, Huizing M, Collen C, Kaufman L, De MJ et al (2008) Tolerance of adjuvant letrozole outside of clinical trials. Breast 17:376–381

    Article  PubMed  CAS  Google Scholar 

  11. Mouridsen HT (2006) Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Curr Med Res Opin 22:1609–1621

    Article  PubMed  CAS  Google Scholar 

  12. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108:1515–1524

    Article  PubMed  CAS  Google Scholar 

  13. Mirmirani P (2013) Managing hair loss in midlife women. Maturitas 74:119–122

    Article  PubMed  Google Scholar 

  14. Mirmirani P (2011) Hormonal changes in menopause: do they contribute to a ‘midlife hair crisis’ in women? Br J Dermatol 165(Suppl 3):7–11

    Article  PubMed  CAS  Google Scholar 

  15. Atanaskova MN, Bergfeld WF (2013) Hair: what is new in diagnosis and management? Female pattern hair loss update: diagnosis and treatment. Dermatol Clin 31:119–127

    Google Scholar 

  16. Ohnemus U, Uenalan M, Inzunza J, Gustafsson JA, Paus R (2006) The hair follicle as an estrogen target and source. Endocr Rev 27:677–706

    Article  PubMed  CAS  Google Scholar 

  17. Yip L, Rufaut N, Sinclair R (2011) Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol 52:81–88

    Article  PubMed  Google Scholar 

  18. Lynfield YL (1960) Effect of pregnancy on the human hair cycle. J Invest Dermatol 35:323–327

    PubMed  CAS  Google Scholar 

  19. Rossi A, Iorio A, Scali E, Fortuna MC, Mari E, Maxia C et al (2013) Aromatase inhibitors induce ‘male pattern hair loss’ in women? Ann Oncol 24:1710–1711

    Article  PubMed  CAS  Google Scholar 

  20. Goss PE, Clark RM, Ambus U, Weizel HA, Wadden NA, Crump M et al (1995) Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin Cancer Res 1:287–294

    PubMed  CAS  Google Scholar 

  21. Forsythe LP, Helzlsouer KJ, MacDonald R, Gallicchio L (2012) Daytime sleepiness and sleep duration in long-term cancer survivors and non-cancer controls: results from a registry-based survey study. Support Care Cancer 20:2425–2432

    Article  PubMed  Google Scholar 

  22. Yip L, Zaloumis S, Irwin D, Severi G, Hopper J, Giles G et al (2009) Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol 161:289–294

    Article  PubMed  CAS  Google Scholar 

  23. Price VH (2003) Androgenetic alopecia in women. J Investig Dermatol Symp Proc 8:24–27

    Article  PubMed  Google Scholar 

  24. Liedtke S, Schmidt ME, Vrieling A, Lukanova A, Becker S, Kaaks R et al (2012) Postmenopausal sex hormones in relation to body fat distribution. Obesity (Silver Spring) 20:1088–1095

    Article  CAS  Google Scholar 

Download references

Acknowledgments

Dr. Gallicchio is a recipient of a Health Disparities Career Catalyst Grant from Susan G. Komen for the Cure (KG110356).

Author information

Authors and Affiliations

  1. The Prevention and Research Center, The Weinberg Center for Women’s Health and Medicine, Mercy Medical Center, 227 St. Paul Place, Baltimore, MD, 21202, USA

    Lisa Gallicchio, Carla Calhoun & Kathy J. Helzlsouer

  2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Lisa Gallicchio & Kathy J. Helzlsouer

  3. Department of Epidemiology and Public Health, University of Maryland, Baltimore, Baltimore, MD, USA

    Lisa Gallicchio

Authors
  1. Lisa Gallicchio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carla Calhoun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathy J. Helzlsouer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa Gallicchio.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gallicchio, L., Calhoun, C. & Helzlsouer, K.J. Aromatase inhibitor therapy and hair loss among breast cancer survivors. Breast Cancer Res Treat 142, 435–443 (2013). https://doi.org/10.1007/s10549-013-2744-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-013-2744-2

Keywords

Search

Navigation